Pharmacological inhibition of the MAPK pathway members BRAF and MEK or monoclonal antibodies against immune checkpoint markers CTLA-4 and PD-1 have provided metastatic melanoma patients with previously unattainable opportunities for meaningful and durable responses. This evidence concerns the gene BRAF and metastatic melanoma.